A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.
By inhibiting a certain protein, the researchers were able to reduce the signals that trigger an inflammation. The study is published in Science and was done in collaboration with the University of Texas Medical Branch, Uppsala University and Stockholm University.
“We’ve developed a new drug molecule that inhibits inflammation,” says Professor Thomas Helleday, at the Department of Oncology-Pathology, Karolinska Institutet, Sweden, who co-led the study with Dr Torkild Visnes and Dr Armando Cázares-Körner. “It acts on a protein that we believe is a general mechanism for how inflammation arises in cells.”
The discovery is the result of many years of research by Thomas Helleday’s group on how DNA is repaired by the body. One of the objectives has been to fight cancer by targeting damage to the tumour cells’ DNA. Several breakthroughs have already been reported, which have led, amongst other things, to a new treatment for congenital breast and ovarian cancer using so-called PARP inhibitors, which has been available for some years.
Trials on mice
It was when developing a new molecule for inhibiting the enzyme that repairs oxygen damage to DNA that the researchers found, to their surprise, that it also dampened inflammation. It turned out that the enzyme OGG1, apart from repairing DNA, also triggers inflammation.
The inhibitor blocks the release of inflammatory proteins, such as TNF alpha. In trials on mice with acute pulmonary disease, the researchers succeeded in dampening the inflammation.
“This discovery could give rise to a new treatment for a very serious condition,” says Professor Helleday. “We’ll now be developing our OGG1 inhibitor and examining whether it can lead to new treatments for inflammatory diseases in order to cure or relieve diseases such as sepsis, COPD and severe asthma.”
The discovery was made in collaboration with Professor Istvan Boldogh from the University of Texas Medical Branch, USA.
The repair pathway on which OGG1 operates was discovered by Tomas Lindahl at Karolinska Institutet in the 1970s, an achievement that earned him the Nobel Prize in Chemistry in 2015.
Collaboration between several universities
The study was a collaboration between Karolinska Institutet, Uppsala University and Stockholm University in Sweden and the University of Texas Medical Branch, USA.
Learn more: New inflammation inhibitor discovered
The Latest on: Anti-inflammatory drug
via Google News
The Latest on: Anti-inflammatory drug
- With ‘bold experiment’ in drug pricing, Arcutis aims to stand out in plaque psoriasison August 1, 2022 at 5:10 pm
The FDA approved Arcutis Biotherapeutics drug Zoryve, a topical treatment for plaque psoriasis. With the decision, the company will proceed with a pricing strategy it believes will speed up insurance ...
- Anti-inflammatory Therapeutics Market Is Set to Fly High in Years to Come with Top Countries Data | 113 Report Pageson July 31, 2022 at 11:19 pm
Aug 01, 2022 (The Expresswire) -- "Anti-inflammatory Therapeutics Market" Insights 2022 By Types (Anti-Inflammatory Biologicals, NSAIDs, ...
- Nanotechnology Could Have a Crucial Role in Inflammatory Bowel Disease Treatmenton July 28, 2022 at 7:45 am
A new review focuses on recent advancements in nanotechnology-based treatments for IBD, mainly targeting inflammation and dysregulated gut microbiomes.
- The effects of CBD in the treatment of COVID-19–related inflammatory symptomson July 28, 2022 at 2:36 am
Some of the common mild symptoms associated with the disease are fever, cough, muscle soreness, fatigue, sore throat, headache, and diarrhea. In the case of severe COVID-19 infection, multiorgan ...
- McGill study finds anti-inflammatory drugs may lead to chronic painon July 26, 2022 at 1:23 pm
Pain is one of the most common reasons why people seek medical attention. The most popular medications people reach for when experiencing pain are anti-inflammatory drugs, such as ibuprofen—also known ...
- Use of anti-inflammatory drug in treating patients with severe COVID-19on July 21, 2022 at 3:26 am
According to a new study from UTHealth Houston and other institutions, an anti-inflammatory drug may have the ability to treat systemic inflammation and brain damage in patients with severe COVID-19 ...
- Incannex receives key ethics approval to start Phase 1 clinical trial of multi-use anti-inflammatory drugon July 20, 2022 at 7:50 pm
Incannex (ASX:IHL) has approval to start clinical trial of multi-use, anti-inflammatory drug for treatment, including rheumatoid arthritis.
- Anti-inflammatory drug may treat brain damage in patients with Covid-19on July 20, 2022 at 7:40 pm
According to a new study from UTHealth Houston and other institutions, an anti-inflammatory drug may have the ability to treat systemic inflammation and brain damage in patients with severe Covid ...
- Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Trends, Growth Rate, Consumption By Regional Data And Forecast 2022-2031on July 13, 2022 at 1:17 am
The Non-steroidal Anti-inflammatory Drugs (NSAIDs) market studied is expected to grow with an estimated CAGR of 5.2%, over the forecast period. COVID-19 has become a major public health problem.
via Bing News